Charles River Laboratories
NYSE: CRL · HEALTHCARE · DIAGNOSTICS & RESEARCH
Updated 2026-06-05
Charles River Laboratories (CRL) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $164.37M | $284.25M | $279.95M | $225.04M | $169.01M | $205.28M | $207.90M | $207.14M | $251.05M | $286.36M | $298.32M | $316.26M | $441.14M | $480.94M | $546.58M | $760.80M | $619.64M | $683.90M | $734.58M | $737.65M |
| Capital expenditures | $181.75M | $227.04M | $197.08M | $80.01M | $42.86M | $49.14M | $47.53M | $39.15M | $56.92M | $63.25M | $55.29M | $82.43M | $140.05M | $140.51M | $166.56M | $228.77M | $324.73M | $318.53M | $232.97M | $219.15M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $21.09M | $21.09M | $24.33M | $23.81M | $25.53M | $21.71M | $21.86M | $24.54M | $31.04M | $40.12M | $43.64M | $44.00M | $47.35M | $57.27M | $56.34M | $71.47M | $73.62M | $72.05M | $69.89M | $71.08M |
| Free cash flow | $-17.38M | $57.21M | $82.87M | $145.03M | $126.15M | $156.14M | $160.37M | $167.99M | $194.13M | $223.11M | $243.03M | $233.83M | $301.09M | $340.42M | $380.01M | $532.03M | $294.91M | $365.37M | $501.61M | $518.49M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | $1.92M | $1.92M | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | $34.55M | $46.59M | $45.65M | — | $25.60M | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $-3.41M | $-110.25M | $40.78M | $46.24M | $4.10M | $-42.08M | $-321000.00 | $37.01M | $44.20M | $31.37M | $-7.72M | $-4.54M | $-30.68M | — | — | — |
Frequently asked questions
What is Charles River Laboratories's revenue?
Charles River Laboratories's trailing twelve-month revenue is $4.03B. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is CRL?
In its most recent fiscal year, CRL ran a gross margin of 30.52%, an operating margin of 12.65%, and a net margin of -3.59%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does CRL generate?
CRL produced $518.49M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is CRL's balance sheet healthy?
CRL holds $213.77M in cash and equivalents against $2.11B in long-term debt, on $3.16B of shareholder equity. That debt is best read against the cash flow the business throws off each year.